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Seed oil of Brucea javanica (BJO) is extracted from the seeds of herb medicine Brucea javanica (L.), and its emulsion formulation
(BJOE) has been used clinically to treat carcinomas for many years in China. The antileukemia potential of BJO was investigated
in human acute myeloid leukemia cell lines (AML) U937 and HL-60 in vitro and in a mouse U937 xenograft tumor model.
BJO induced AML cell apoptosis through activation of caspase-8 and modulation of apoptosis-related proteins. Meanwhile, the
inhibition of survivin and XIAP increased the cytotoxicity of BJO. Consistent with these ﬁndings, BJO also increased subG1 phase
cells and cause PARP cleavage in AML patients’ leukemia cells. In contrast, only weak cytotoxicity of BJO was found in peripheral
blood lymphocytes (PBLs) of healthy volunteers. Moreover, oleic acid and linoleic acid were found to be the active components of
BJO. Our study provided strong evidence for the ﬁrst time that BJO induced apoptosis of both cultured and primary AML cells.
Furthermore,intravenousinjectionofBJOsigniﬁcantlyinhibitedU937tumorgrowthinthexenograftmousemodel.Theseresults
suggest that BJO may have a therapeutic role in the treatment of human leukemia.
1.Introduction
Seed oil of Brucea javanica (BJO) is extracted from the seeds
of Brucea javanica (L.), a traditional herbal medicine, by
using circulation extraction method in petroleum ether. Its
emulsion formulation, Brucea javanica oil emulsion (BJOE),
has been used clinically to treat carcinomas for many years
in China; its clinical indications include lung cancer, prostate
cancer, and gastrointestinal cancer [1–3].
PreviousstudieshavefoundthatBJOcaninducecytotox-
ic eﬀects through apoptosis induction. It has been reported
that BJO induced apoptosis at low concentrations and
induced necrosis at higher concentrations [4]. BJO induces
apoptosisviadownregulatingexpressionofp53,Bcl-2,c-myc
in hepatocellular and bladder cells [2, 4] and upregulating
expression of Fas in leukemia cells [5]. Moreover, BJO can
arrest the cell cycle in G0/G1 phase [6, 7] to inhibit cell
growth. It seems that BJO is a potent apoptotic agent to
cancer cells. However, the active components of BJO are
still not clear. Also, whether BJO can be used to treat acute
myeloid leukemia (AML) and its underlying mechanisms are
still unknown.
Although conventional chemotherapy of AML with
either cytarabine or daunorubicin given as a single agent
induces complete remission in ∼30% to 40% of patients and
combination treatment with both agents induced complete
remission in more than 50% of patients [8]; however, only
20% to 30% of patients enjoy long-term disease-free survival
[9]. Thus, there is a need for new agents for the treatment of
AML.
It has been estimated that approximately 65% of
clinically used anticancer agents have a root of natural
products [10]. Both homoharringtonine and etoposide are
plant original medicines which have signiﬁcant antileukemia
eﬀect [11–13] in clinical studies in [14]. However, clinical
studies of these two products showed that myelosuppres-
sion, cardiovascular, and gastrointestinal events were usually
accompanied with their anticancer eﬀects [14]. While, in2 Evidence-Based Complementary and Alternative Medicine
the clinical studies of chemotherapy combined with the
emulsion of BJO, it has been reported that the toxicity of
combination group is much less than the chemotherapy
group [15, 16]. Therefore, to examine the potential of BJO
forclinicalapplicationsinthetreatmentofAMLandidentify
the active components of BJO would be very signiﬁcant.
Inthisstudy,ourresultsshowthatBJOinducesapoptosis
through both mitochondrial pathway and death receptor
pathway. Its apoptotic eﬀect on AML cells was much more
potent than on normal PBLs from healthy volunteers. BJO
can also inhibit tumor growth in mouse U937 xenograft
tumor model and induce apoptosis in AML patients’
leukemia cells. These combined observations suggest that
BJO has a high potential for clinical application in the
treatment of AML. The major active components of BJO
were also identiﬁed as oleic acid and linoleic acid in our
study.
2.MaterialsandMethods
2.1. Reagents. Brucea javanica oil emulsion (Lot no. 060724)
and soybean phospholipids (Lot no. 060724, emulsifying
agent)wereprovidedbyShenyangYaodaPharmaceuticalCo.
Ltd. (Shenyang, Liaoning, China). Oleic acid (cell culture
tested, Lot no. O1383) and linoleic acid (cell culture tested,
Lot no. L1012) were purchased from Sigma-Aldrich (St.
Louis, MO).The etoposide emulsion was generously donated
by Prof. Xing Tang from the Department of Pharmaceu-
tics, Shenyang Pharmaceutical University. Trizol was from
Invitrogen Corporation (USA) and the Revert Aid Mulv RT
Kit was from Fermentas Inc. (Hanover, USA). Tag DNA
polymerase and primers were from Takara (Tokyo, Japan)
while the poly-(ADP-ribose)-polymerase (PARP) antibody
was from Boehringer Mannheim (Indianapolis, IN). The
antibodies for caspase-3 and Bcl-2 were purchased from BD
Biosciences (San Diego, CA), while the antibodies for Bax
and β-actin were from Santa Cruz Biotechnology (Santa
Cruz, CA). The other antibodies were from Cell signaling
Technology Inc (UK). Lympholyte-human 1077 (15min,
280×g) was from Tianjin TBD Biotek Ltd. Co. (Tianjin,
China).
Seventoeight-week-oldmaleBalb/cnudemicewerepur-
chased from National Rodent Laboratory Animal Resources
(Beijing). All other reagents were purchased from Sigma (St.
Louis, MO).
2.2. The Preparation of Brucea Javanica Oil Emulsion (BJOE).
The BJO was extracted from the seeds of Brucea Javanica
by using circulation extraction method in petroleum ether
(boiling range: 60–90◦C). After extracting, the extraction
was heated to evaporate petroleum ether and crude BJO
was obtained. The active carbon and crude BJO were mixed
together and the mixture was kept 90◦Cf o r3 0m i n u t e s .
When cooling to 80◦C, the mixture was ﬁltered through a
stainless steel B¨ uchner’s funnel with medium speed ﬁlter
paper and clarifying ﬁlter paper. The reﬁned BJO was emul-
siﬁed by adding soybean phospholipids. (The prescription
and preparation methods were provided by Shenyang Yaoda
Pharmaceutical Co. Ltd. Shenyang, Liaoning, China.)
2.3. Cell Culture. Leukemia cell lines U937 and HL-60
cells were cultured in RPMI 1640 supplemented with
100units/mL penicillin, 100μg/mL streptomycin, 1mmol/L
L-glutamine, and 10% heat-inactivated fetal bovine serum.
Cells were maintained in 75cm2 ﬂasks in a humidiﬁed
incubator at 37◦Cw i t h5 %C O 2. All these cell lines were
generous gifts from Dr. Y. K. Jing, the Mount Sinai School
of Medicine, New York, US.
2.4. Samples from Patients and Healthy Volunteers. Fifteen
newly diagnosed AML patients (M5 and M2) and 4 healthy
volunteers entered this study between November 2008 and
June 2009 at Shenyang Military General Hospital. The
diagnoses were based on clinical data (history, symptoms,
and physical ﬁndings), examination of peripheral blood,
and bone marrow according to the French-America-British
(FAB) classiﬁcation and karyotype identiﬁcation. The main
clinical patient data at diagnosis are summarized in Table 1.
Blood samples were taken from nonsmoking healthy volun-
teers who had not been treated with any anticancer drugs for
at least 6 months. The study was approved by the Medical
Ethical Committee of Shenyang Military General Hospital,
and informed consent was obtained from each patient and
volunteer.
2.5. Isolation of Human Peripheral Blood Lymphocytes.
Human peripheral blood lymphocytes were isolated as
described previously [17]. In brief, after diluting blood with
PBS, lymphocytes were isolated by centrifugation over a
density gradient of lympholyte-human 1077 for 15min at
280g. The cells were washed with PBS twice then suspended
in complete RPMI 1640 with 10% fetal bovine serum. The
viability of the isolated lymphocytes was measured by trypan
blue exclusion assay and found to be about 99%.
2.6. MTT Assay. Leukemia cells were seeded at a density
of 1.5 × 105 on 96-well plates and incubated with emul-
sifying agent (soybean phospholipids, 1:200, v/v), various
concentrations of BJO (67.5μg/mL, 125μg/mL, 250μg/mL,
500μg/mL, 1000μg/mL), and etoposide (positive control,
10μmol/L) or oleic acid (37.5μg/mL, 75μg/mL, 150μg/mL)
or linoleic acid (56.25μg/mL, 112.5μg/mL, 225μg/mL) for
6h. Then 10μL MTT solution (2.5mg/mL in PBS) was
added to each well, and the plates were incubated for an
additional 3h or 4h at 37◦C. After centrifugation (2500rpm,
10min), the medium with MTT was aspirated, followed by
the addition of 100μL DMSO. The optical density of each
well was measured at 492nm with a Biotek Synergy TM HT
Reader.
2.7. Evaluation of Apoptosis. Apoptotic cells were evaluated
by morphologic observation, DNA fragmentation assay, and
cell cycle examination. For morphologic evaluation, cells
were stained with Hochest33258 (10μg/mL) and AO/EB
(10μg/mL) and observed by ﬂuorescence microscopy. ForEvidence-Based Complementary and Alternative Medicine 3
Table 1: Clinical data of AML patients and apoptosis rate induced in vitro by BJO.
Patient no. Sex/Age HB (g/L) WBC (×109) Platelet (×1012/L) APL Cell (%) in BM AML type Apoptosis rate (%) (500μg/mL)
1 F/22 44 57.8 1.23 67 M5 51.31
2 M/58 109 30.0 1.73 77.5 M5 38.98
3 M/65 98 283.3 3.80 86 M5 53.79
4 F/25 64 125.0 18.6 54 M5 38.04
5 F/55 116 255 3.20 91.5 M5 96.23
6 M/65 66 171.6 1.9 67 M5 45.09
7 M/50 128 247 3.3 68.5 M5 53.44
8 M/46 84 26.3 2.3 88.5 M5 75.92
9 M/45 46 1.7 1.23 50 M5 28.80
10 M/63 50 75.0 1.28 76.8 M5 90.04
11 M/63 64 42.9 1.8 52 M5 53.79
12 F/47 85 439.6 3.1 52 CML-M5 29.35
13 M/59 77 23.3 2.67 27.5 CML-M5 92.48
14 F/45 56 41.9 3.45 26.4 CML-M5 63.84
15 F/62 96 235.6 3.8 90.0 M2 64.26
Note: The patients’ leukemic cells were treated with or without BJO for 6 h. Percentage of cells in the subG1 phase was measured using FACS as described in
Materials and Method.
the DNA fragmentation assay, cells were washed with PBS
and harvested by centrifugation. Cells were suspended in
200μL PBS solution, then 10μLR N a s eA( 2 0m g / m L ,S i gm a -
Aldrich) was added. After the sample had been incubated
at 37◦C for 45min, the genomic DNA mini preparation kit
with a spin column was used to obtain the genomic DNA.
The genomic DNA was separated on a 1.8% agarose gel
with 1μg/mL ethidium bromide. The cell cycle examination
was carried out as described elsewhere [18]. In brief, cells
were collected and ﬁxed in ice-cold 70% ethanol overnight.
Then, the cells were washed with PBS by centrifugation
and incubated with 200μg/mL RNase A for 30min at
37◦C. Before measuring the DNA content by ﬂow cytometry
(Becton Dickinson, San Jose, CA), 30μL propidium iodide
solution (1mg/mL) was added. Data were analyzed using
CELLQuest (Becton Dickinson) software.
2.8. Examination of Intracellular Reactive Oxygen Species
(ROS) Release. Intracellular hydrogen peroxide levels were
monitored by ﬂow cytometry after staining with DCFH-
DA (6-carboxy-2 ,7 -dichlorodihydroﬂuorescein diacetate)
[19]. Brieﬂy, cells in a logarithmic growth phase (1 ×
105 cells/mL) were labeled with 5μmol/L DCFH-DA for 1
h and then treated with various concentrations of BJO.
The cells were washed with PBS and then analyzed by ﬂow
cytometry (Becton Dickinson, San Jose, CA) with excitation
and emission wavelengths of 488 and 525nm, respectively.
C e l l ss t i m u l a t e dw i t h1 0 0μmH 2O2 for 1h were used as a
positive control.
2.9. Mitochondrial Membrane Potential Assay. The mito-
chondrial membrane was monitored using rhodamine 123
(Rh123) ﬂuorescent dye (Ex/Em = 507/529) which is selec-
tively taken up by mitochondria in a manner proportional to
the mitochondrial membrane potential [20]. In brief, cells
treated with various concentrations of BJO were collected
and washed with PBS then incubated with 0.5μg/mL Rh123
in the dark for 30min at 37◦C. The cells were washed with
PBSthenanalyzedbyﬂowcytometry(BectonDickinson,San
Jose, CA).
2.10. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Total RNA was extracted with Trizol according to
the manufacturer’s protocol. Total RNA (1μg) was reverse
transcribed to cDNA using a reverse transcription system
following the manufacturer’s instruction manual. The cDNA
was then ampliﬁed by PCR with speciﬁc primers of Bax
sense; 5 -ACC AAG AAG CTG AGC AGT GTC-3 ; anti-sense
5 -TGT CCA GCC CAT GAT GGT TC-3 , 258 bp [21], Bcl-
2s e n s e ;5  -CGA CGA CTT CTC CCG CCG CTA CC-3 ;
anti-sense 5 -CCG CAT GCT GGG GCC GTA CAG TTC
C-3 , 318bp [22], PCNA sense; 5 -AAA CCA GCT AGA
CTT TCC TC-3 ; anti-sense 5 -TCA CGC CCA TGG CCA
GGT TG-3 , 274bp [23], pro-caspase3 sense 5 -TAA ATC
CCA CTG CCA CGG TCG-3 ; anti-sense 5 -TGG AAC AAA
TGG ACC TGT TGA CC-3 , 453bp; survivin sense 5 TGC
CTG GCA GCC CTT TCT CA 3 ; anti-sense 5  GAT GGC
ACG GCG CAC TTT CT 3 , 383 bp and GAPDH sense 5 -
TGA TGA CAT CAA GAA GGT GGT GAA G-3 ; anti-sense
5 -TCC TTG AGG CCA TGT GGG CCAT-3 , 240bp [24].
The annealing temperatures were 61◦C, 60◦C, 55◦C, 55◦C,
and 55◦C, respectively. The PCR products were separated on
1.2% agarose gels and visualized with 0.5μg/mL ethidium
bromide.
2.11. Western Blotting Analysis. Protein extracts (45μg)
were prepared with radioimmunoprecipitation assay lysis4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Cytotoxic eﬀects of BJO on diﬀerent tumor cell lines. HL-60 and U937 cells were treated with emulsiﬁer (negative control), etoposide
(10μmol/L, positive control), or various concentrations of BJO as indicated for 6 hours. (a) Cell viabilities were determined by MTT
assay. ∗∗∗P<. 001 (b) U937 cell morphology analysis following treatment with BJO. AO/EB and Hochest3325 were used to stain cells and
the cellular ﬂuorescent changes were observed using ﬂuorescence microscope. Results were obtained from three separate experiments. (c)
Apoptotic cells were evaluated by cell cycle analysis. Percentage of cells in the subG1 phase was measured using ﬂow cytometry as described
in Materials and Method. (d) Western blotting analysis of PARP. β-actin is shown as a loading control. (e) DNA fragmentation analysis. The
level of DNA fragmentation was determined as described in Materials and Method.
buﬀer (50mmol/L Tris-HCL, 150mM/L NaCL, 0.1% SDS,
1% NP-40, 0.5% sodium deoxycholate, 1mmol/L phenyl-
methylsulfonyl ﬂuoride, 100μmol/L leupeptin, and 2μg/L
aprotinin) and were subjected to electrophoresis on 8% or
12% SDS-polyacrylamide gels and transferred to 0.45μm
nitrocellulose membranes. The membranes were stained
with 0.2% Ponceau S red to check equal protein loading
and transfer. After blocking with 5% skimmed milk, the
membranes were incubated with antibodies to PARP, Bcl-2,
Bax,Bid,procaspase-3,caspase-8,c-FLIP(L/S)(CellularFLICE
inhibitory protein), XIAP, DR4 (Death Receptor 4), DR5
(DeathReceptor 5), MCL-1, or β-actinovernight at 4◦C. The
membranes were incubated with horseradish peroxidase-
conjugated secondary antibody, and the immunocomplexes
were visualized by ECL western blotting detection reagents.
The protein concentrations in the lysate were determined
using the BCA protein assay kit.
2.12. In Vivo Antileukemia Eﬀects on Xenograft Transplanta-
tion. To determine the in vivo antitumor activity of BJO,
viable U937 cells (3 × 107/200μL PBS per mouse), as
conﬁrmed by trypan blue staining, were subcutaneously
injected into the right ﬂank of 7- to 8-week-old maleEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀect of BJO on ROS release and mitochondrial membrane potential (MMP) collapse in U937 cells. U937 cells were treated with
etoposide (10μmol/L) or various concentrations of BJO as indicated for 6h. (a) U937 cells were labeled with 5 μmol/L DCFH-DA for 1h
prior to the treatment with BJO. The addition of 100 μmol/L H2O2 for 1 h was used as a positive control for the H2O2 level. (b) Disruption
of MMP was determined according to changes in ﬂuorescence density using rhodamine 123. (c, d, and e). ROS accumulation, MMP, and cell
cycle examination of U937 pretreated with antioxidants. Cells were pretreated with catalase (500U/mL) or N-acetylcysteine (10mM) for 4
hours, followed by treatment with or without BJO for another 6 h. ROS level, MMP, and cell cycle were measured using ﬂow cytometry as
described in Materials and Methods.
Balb/c nude mice. When the average s.c. tumor volume
reached 100mm3, the mice were randomly divided into ﬁve
treatment groups, including control (saline only), etoposide
injection(2.5mg/kg,viatailvein,daily),andBJO(5.5mg/kg,
16.5mg/kg, 49.5mg/kg, via tail vein, daily). Tumor size was
measured once every two days with a caliper (calculated
volume = shortest diameter2× longest diameter/2). Body
weight, diet consumption, and tumor size were recorded
once every two days. After 10 days, the mice were sacriﬁced
andthetumorswereexcisedandweighed.Onepartoftumor
tissue was ﬁxed in formalin, and the remaining part was
stored at −80◦C until further analysis. Blood was collected
in heparinized tubes by cardiac puncture.
2.13. Measurement of Components in the Emulsion of BJO
by Gas Chromatography-Mass Spectrometry. The total com-
ponents of the emulsion of BJO were determined by gas
chromatography-mass spectrometry (GC-MS), and oleic
acid was used as a reference. Brieﬂy, sodium chloride and 5
drops of hydrochloric acid were added to BJOE which was
kept in a 65◦Cwaterbathuntiloil-waterseparation.Afterthe
solution cooled to room temperature, BJOE was extracted
with petroleum ether, and then acetone. Methanolic sodium
hydroxide solution (0.5mol/L) was added to the test solution
in the 65◦C water bath for saponiﬁcation until all the oil
dropletsdissolved.Aftercoolingtoroomtemperature,a13%
methanolic solution of boron trichloride was added to the
solution in the 65◦C water bath and it was allowed to stand
for 15min. Then, 2mL N-hexane was added to the test solu-
tion in an ice-water bath, and shaken for 2min. A saturated
sodiumchloridesolutionwasaddeduntil theN-hexanelayer
rose to the bottle neck and then the N-hexane solution was
removed from the bottle. Dried sodium sulfate was added
to the N-hexane solution to obtain the test solution. The6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of BJO on apoptotic proteins. AML cells were treated with etoposide (10μmol/L) and various concentrations of BJO as
indicated for 6 hours. (a) The mRNA levels of apoptosis-related proteins were examined by RT-PCR as described in Materials and Methods.
(b, c, and d) Western blotting analysis of procaspase-3, procaspase-9, Bcl-1, Mcl-1, Bax, Bid, pro-caspase-8, c-FLIP(L/S), DR4, pro-DR5, Fas,
XIAP and Survivin. Lane 1 and Lanes 3–5: cells were treated with or without BJO. Lane 2: cells were treated with etoposide (10μmol/L). The
level of each protein was determined using speciﬁc antibodies as described in Materials and Method.
test solution was then transferred to a Suplecowax-10 fused-
silica capillary column (30m × 250μm × 0.25μm), using
polyethylene −20M as a loading agent. The sample-input
temperaturewas250◦C;thedetectortemperaturewas250◦C;
the column temperature was 220◦C; the nitrogen ﬂow rate
was 0.5 ml/min and the ﬂow ratio was 20:1.
2.14. Data Analysis. Results were expressed as the mean ±
SE of three experiments. One-way ANOVA followed by
Dunnett’s t-test was used for statistical analysis (SPSS 13.0
software, SPSS, USA).
3. Results
3.1. BJO-Induced Apoptosis in Acute Myeloid Leukemia Cell
Lines. In this study, the eﬀect of BJO on the viability of
HL-60 and U937 cells was examined by MTT assay. Cells
were treated with or without BJO at diﬀerent concentrations
(67.5, 125, 250, and 500μg/mL). As shown in Figure 1(a),
after treatment for 6h, BJO signiﬁcantly reduced the cell
viability in a concentration-dependent manner with IC50
values of 312.7 and 265.4μg/mL for HL-60 and U937
cells, respectively. Soybean phospholipids (the emulsiﬁer of
BJOE) did not aﬀect the cell viability in either of those cell
lines.
The abnormalities of cell morphology were examined
using ﬂuorescence microscopy. Cells treated with BJO at
diﬀerent concentrations demonstrated morphology charac-
teristic of apoptosis, such as chromatin condensation and
formation of apoptotic bodies (Figure 1(b)). To further
investigate the mode of cell death induced by BJO, U937 and
HL-60 cells were stained with propidium iodide after BJO
treatment. It was shown that BJO produced concentration-
dependent signiﬁcant increases in the proportions of apop-
totic cells without G0/G1 or G2/S phase arrest (Figure 1(c)).
Moreover, it was found that PARP, a substrate of caspase-
3, was also cleaved by BJO (Figure 1(d)). BJO could also
induce marked DNA fragmentation in U937 and HL-60
cells (Figure 1(e)), while it had no eﬀect on mRNA level
of proliferating cell nuclear antigen (PCNA), an essential
component of the replication mechanism (data not shown).
All these results indicated that BJO induced apoptotic death
of U937 and HL-60 cells.
3.2. The Reduction in Mitochondrial Membrane Potential
( M M P )C a u s e db yR e a c t i v eO x y g e nS p e c i e s( R O S )P r o d u c t i o n
Is Not the Only Mediator of BJO-Induced Apoptosis. ROS
levels were determined in U937 and HL-60 cells after
BJO treatment using a sensitive ﬂuorescent probe, DCFH-
DA. Intracellular ROS levels increased in a concentration-
dependent manner after BJO treatment for 6h (Figure 2(a)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Western blotting analysis of PARP in primary leukemia cells from AML patients. The cells were treated with or without BJO.
β-actin was also detected as the loading control. Data were represented as mean ± SE of three separate experiments, ∗∗∗P<. 001. The data
was a representative of one result of ﬁfteen patients.
Table 2: The component of BJOE.
Name Structural formula Percentage (%) Retention time (min)
1 Phenol
OH
0.59 5.433
2 Hexadecanoic acid O
O
11.75 8.309
3 Octadecanoic acid O
O
5.45 13.531
4 9-Octadecenoic acid O
O
29.24 14.330
5 9E,12Z-Octadecadie-noic acid O
O
44.85 16.225
6 9Z,12Z,15Z-Octade-catrienoic acid O
O
4.22 19.117
Note: The total components of BJOE were measured by GC-MS as described in Materials and Method.
Since the impairment of mitochondrial function has been
considered to be a key event in the ROS-mediated apoptotic
pathway [25, 26], the MMP in U937 and HL-60 was
determined. As shown in Figure 2(b), a signiﬁcant reduction
in MMP was observed in U937 cells. Similar results were also
observedinHL-60cells(datanotshown).Thesedatasuggest
that BJO may induce apoptosis through a mitochondria-
mediated pathway due to ROS production.
To examine whether the apoptosis induced by BJO was
uniquely caused by MMP collapse, two antioxidants, catalase8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of BJO on human peripheral blood lymphocytes and AML cells. AML cells and PBLs were treated with emulsiﬁer (negative
control), etoposide (10μmol/L, positive control), or indicated concentrations of BJO for 6 hours. (a) Cell viabilities were determined by
MTT assay. ∗∗∗P<. 001 (b) Apoptotic cells were evaluated by cell cycle analysis. Percentage of cells in the subG1 phase was measured using
FACS as described in Materials and Method. (c) Disruptions of MMP were determined by changes in ﬂuorescence density using rhodamine
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Figure 6: BJO inhibits the growth of mouse tumors in U937 xenograft model. (a) U937 cells (3 × 107/200μL PBS per mouse) were injected s.c.
intotherightﬂankofmice.MicewereinjectedwithsalineordesignateddosesofBJOasdescribedinMaterialsandMethods.Tumorsizewas
measured once every two days with a caliper (calculated volume = shortest diameter2× longest diameter/2). (b) 11th day after intravenously
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(CAT) and N-acetylcysteine (NAC, a precursor of reduced
glutathione and a free radical scavenge) were used. Neither
NAC nor CAT per se regulated apoptosis, ROS production,
or MMP in U937 and HL-60 cells, respectively, (data not
shown). Pretreatment with either CAT or NAC eﬀectively
reversed the increase in ROS release and decrease in MMP
in U937, which was induced by BJO treatment for 6 h
(Figures 2(c) and 2(d)). However, neither CAT nor NAC
aﬀected the apoptosis induced by BJO (Figure 2(e)). Similar
results were also observed in HL-60 cells (data not shown).
These results suggested that the reduced MMP caused by
ROS production may not be the only downstream eﬀect for
BJO-induced apoptosis.
3.3. BJO-Induced Apoptosis in U937 Cells Accompanied by a
Reduction in Protein Levels of c-FLIP(L/S),M c l - 1 ,B c l - 2 ,X I A P ,
andSurvivin. Caspaseshavebeenshowntoplaycriticalroles
in the initiation and maintenance of apoptosis [27]. Thus,
the activation of caspases in BJO-treated cells was examined.
AsshowninFigures3(a)and3(b),BJOactivatedprocaspase-
3 resulting in the cleavage of PARP. Moreover, as the caspase
member acting on the mitochondrial pathway, the protein
levels of procaspase-9 were reduced after BJO treatment.
Caspase-8 was also activated by BJO (Figure 3(b)).
To discover the relationship between BJO and the
activation of the death receptor pathway, the death receptors
including Fas, DR4, and DR5 were examined. As shown in10 Evidence-Based Complementary and Alternative Medicine
I
o
n
a
b
u
n
d
a
n
c
y
(
%
)
a
b
c
d
e
f
Retention time(min)
5 1 01 52 02 53 0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
×105
Figure 7: Total contents of BruceaJavanica oil emulsion. The content
ofBJOEwasanalyzedbygaschromatography-massspectrometryas
described in Materials and Methods. The percentages of six compo-
nents in BJOE were phenol (a; C6H6O, 0.59%), hexadecanoic acid
(b; C17H34O2, 11.75%), octadecanoic acid (c; C19H38O2, 5.45%),
9-octadecenoic acid (d; C19H36O2, 29.24%), 9,12-octadecadienoic
acid (e; C19H34O2, 44.85%), and 9,12,15-octadecatrienoic acid (f;
C19H32O2, 4.22%). Representative graph of two runs.
Figure 3(c), the expression of Fas, DR4, or DR5 was not
altered by BJO. c-FLIP(L/S),which is an inhibitor of apoptosis
downstream of the death receptors Fas, DR4, and DR5 [28],
was signiﬁcantly reduced after BJO treatment, which might
cause the activation of caspase-8 (Figure 3(c)). It was also
found that Bid, which is not only a substrate of caspase-8 but
alsoabridgeproteinofthemitochondrialpathwayanddeath
receptor pathway, was also cleaved by BJO (Figure 3(b)).
These results suggest that the activation of the death receptor
pathway by BJO may be caused by the downregulation of c-
FLIP(L/S).
To examine the relationship between BJO and mito-
chondrial disruption, the Bcl-2 family antiapoptotic pro-
teins which are the critical determinants of mitochondrial-
dependent caspase activation were examined [29]. As shown
in Figures 3(a) and 3(b), the mRNA level of Bcl-2 and the
protein levels of Bcl-2 and Mcl-1 were reduced following
BJO treatment, while the protein level of Bax remained
unchanged. This suggests that the activation of the mito-
chondrial pathway may be caused by the downregulation of
Mcl-1 and Bcl-2.
In addition, BJO signiﬁcantly reduced the protein levels
of XIAP and survivin (Figures 3(a) and 3(d)). Both of them
are inhibitors of caspase-9 and caspase-3 [30]. The mRNA
levels of survivin were also reduced (Figure 3(a)). Taken
together, these data indicated that BJO-induced apoptosis in
U937 and HL-60 cells activated both the mitochondrial and
thedeathreceptorpathway,accompaniedbydownregulation
of c-FLIP(L/S), Mcl-1, Bcl-2, and activation of Bid. Also, the
reduction in XIAP and survivin could enhance the activity of
the caspases.
3.4. BJO Introduces Apoptotic Death of Primary Human
Leukemic Cells. Since BJO treatment can induce apoptosis in
AML cell lines, it would be interesting to see whether BJO
could be used clinically to treat AML. The apoptotic eﬀect
of BJO on AML patients’ leukemic cells (including M2 and
M5) was examined in vitro using FACS and Western blotting
analysis. All 15 samples were treated with BJO for 6 h. As
Table 1 shows, the percentages of cells in the subG1 phase
were increased in a concentration-dependent manner in all
samples. In addition, as shown in Figure 4,c l e a v e dP A R P
can also be seen in 7 of the 15 cases. These results indicated
that BJO also induced apoptosis in human primary leukemic
cells.
3.5. BJO Is Relatively Noncytotoxic to Normal Peripheral
Blood Lymphocytes. To further examine the cytotoxic eﬀect
of BJO on normal cells, we compared the cytotoxicity of
BJOE on AML cells and normal PBLs using MTT. As
shown in Figure 5(a), the cell viabilities of U937 and HL-
60 were much lower than that of PBLs after BJO treatment,
suggesting that the AML cells were more sensitive to BJO.
Theselectivityindex(SI)ofBJO,whichwasdeterminedfrom
the ratio of the IC50 of the PBLs cells to that of the AML
cells [31], was more than 4.0. In addition, the cell numbers
of PBLs in the subG1 phase were much lower than those of
AML cells (Figure 5(b)). Since the mitochondrial pathway
is involved in chemotherapy-induced apoptosis [32], we also
found that the percentages of cells in PBLs with low MMP
were much lower than those in AML cells (Figure 5(c)).
TheseresultssuggestedthatBJOselectivelyinducesapoptosis
in AMLcellswithlittle toxicity to normal haemopoietic cells.
3.6. Antileukemia Eﬀect of BJO against U937 Leukemia Xen-
o-graft in Nude Mice. We further evaluated the antileukemia
abilityofBJOinamouseU937tumormodel.U937cellswere
subcutaneously injected into the right ﬂank of Balb/c nude
mice and rapidly gave rise to exponentially growing tumors.
When the average tumor volume reached 100 mm3, the
nude mice were intravenously injected with saline, etoposide
(2.5mg/kg),orBJO(5.5,16.5and49.5mg/kg).After10days,
the mean volume of tumors in mice treated with BJO was
much smaller than the tumors in the saline-treated mice
(Figure 6(a)).Correspondingly,tumorweightinBJO-treated
groups was also signiﬁcantly smaller compared with the
saline-treated mice (Figure 6(b)). The tumor in nude mice
withorwithoutBJOtreatmentisshowninFigure 6(c).These
results suggested that BJO also has a signiﬁcant antileukemia
eﬀect in vivo.
3.7. The Active Components of Brucea javanica Oil. The
total components of BJOE were measured by GC-MS. As
shown in Figure 7, there were six components in BJOE:
phenol (0.59%), hexadecanoic acid (11.75%), octadecanoic
acid (5.45%), 9-Octadecenoic acid (oleic acid) (29.24%),
9E,12Z-Octadecadienoic acid (linoleic acid) (44.85%),
and 9Z,12Z,15Z-Octadecatrienoic acid (4.22%) (Table 2).
Among the six components, oleic acid and linoleic acid were
two major components. As shown in Figures 8(a) and 8(b),
both oleic acid and linoleic acid had cytotoxic eﬀect on HL-
60 and U937 cells. Moreover, the mixture of oleic acid and
linoleic acid at the same ratio as in BJO also has cytotoxicEvidence-Based Complementary and Alternative Medicine 11
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Figure 8: Active contents of Brucea Javanica oil. (a) HL-60 and U937 cells were treated with oleic acid (37.5, 75, and 150μg/mL) as indicated
for 6h. (b) HL-60 and U937 cells were treated with linoleic acid (56.25, 112.5, 225μg/mL) as indicated for 6h. (c) HL-60 and U937 cells were
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Middle: oleic acid 75μg/mL & linoleic acid 112.5μg/mL; High: oleic acid 150μg/mL & linoleic acid 225μg/mL) for 6h. (d) U937 and HL-60
cells morphology analysis following treatment with the mixture of oleic acid and linoleic acid. AO/EB was used to stain cells and the cellular
ﬂuorescent changes were observed using ﬂuorescence microscope. Results were obtained from three separate experiments.
eﬀect (Figure 8(c)). The cells treated with the mixture at dif-
ferent concentrations also demonstrated morphology char-
acteristic of apoptosis, such as chromatin condensation and
formation of apoptotic bodies (Figure 8(d)). Since BJOE
was composed of BJO and soybean phospholipids, and
the emulsiﬁer soybean phospholipids do not have cytotoxic
eﬀect, these results suggested that the active components of
BJO were oleic acid and linoleic acid.
4. Discussion
Naturally occurring drugs are playing a signiﬁcant role in
treating AML, including homoharringtonine and etoposide
[14]. While clinical reports had shown that both of them
can induce many adverse eﬀects resulting in the decrease
of the life quality and aggravate the syndrome, like myelo-
suprression. The emulsion of BJO had been clinically used
to treat carcinoma for many years, and the clinical reports
also showed that combination of the emulsion of BJO with
chemotherapy can not only increase the anticancer eﬀect but
also decrease the toxicity of chemotherapy [15, 16].
AlthoughtheemulsionformulationofBJOhasbeenused
clinically in China for more than 20 years to treat carcinoma,
the active components and the molecular mechanisms
remained unknown. The present study ﬁrst showed that
BJO produced a concentration-dependent cytotoxicity to12 Evidence-Based Complementary and Alternative Medicine
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Figure 9: A schematic illustration of signal pathways involved BJO-induced cell apoptosis.
AML cell lines U937 and HL-60. Cell cycle examination,
cleaved PARP, and DNA fragmentation analysis indicated
that the cytotoxic eﬀect of BJO was mediated by induction
of apoptosis.
The multiple pathways involved in the action of BJO
were further identiﬁed (Figure 9). Firstly, BJO induced
mitochondria-initiated apoptosis, including reduction in
MMP and ROS production. Secondly, BJO treatment down-
regulated c-FLIP(L/S), an inhibitor of the death receptors Fas,
DR4, and DR5 [28], and subsequently led to the activation
of caspase-8. Thirdly, BJO also downregulated XIAP and
survivin,twoimportantmembersoftheIAPsfamily[30,33],
and subsequently led to the activation of caspase-9 and
caspase-3. Finally, BJO decreased mRNA and protein expres-
sions of Mcl-1 and Bcl-2, two members of the antiapoptotic
Bcl-2 family proteins. Since the Bcl-2 family proteins are
critical determinants of mitochondrial-dependent caspase
activation [29], downregulation of Mcl-1 and Bcl-2 may
also contribute to mitochondria-initiated apoptosis. Taken
together, it could be proposed that BJO induced apoptosis
in U937 and HL-60 cells via activation of the death receptor
pathway by downregulation of c-FLIP(L/S), and activation
of the mitochondrial pathway by downregulation of Mcl-1
and Bcl-2. In addition, the reduction of XIAP and survivin
could enhance the activity of the caspases (Figure 9). All
these ﬁndings strongly suggest that BJO can be a potential
chemotherapeutic drug for AML.
In addition to the therapeutic eﬀect of anticancer drugs
on malignant cells, chemotherapy usually causes severe
toxicity to normal tissues. The present study showed that the
cytotoxic activity of BJO on normal PBLs was much weaker
than that on AML cells. After BJO treated, the cell numbers
of PBLs in the subG1 phase were much lower than those of
AML cells. Similarly, BJO treatment induced MMP collapse
in AML cells as well as in normal PBLs, but to a much
lesser extent. This suggests that BJO exhibits more selective
cytotoxicity to AML cells [34].
According to the FAB classiﬁcation, the monocytic
leukemia cell line U937 belongs to the AML subtype of M5
and HL-60 belongs to M2 [31]. By using primary leukemic
cells from M5 and M2 patients, we found that BJO could
increase the percentage of subG1 cells, and 7 of 14 M5
patients’ leukemia cells were sensitive to BJO in vitro (>50%
apoptosis). The cleavage of PARP induced by BJO treatment
also conﬁrmed that BJO could induce apoptosis in primary
leukemiccellsfromAMLpatients.Boththeselectivecytotox-
icity and apoptosis inducting eﬀect of BJO imply the thera-
peutic application of BJO in the treatment of AML patients.
Moreover, we further examined the in vivo anticancer
eﬀect of BJO in a nude mouse tumor model. BJO eﬀectively
slowed the tumor growth, even at a lower dose. In the
BJO-treated group, both tumor volume and weight were
signiﬁcantly reduced compared with that of the control
group. These results further conﬁrmed the anticancer eﬀect
of BJO and its clinical potentials.
The total BJO components were determined by gas
chromatography-mass spectrometry (GC-MS) and it was
found that oleic acid and linoleic acid were two major
components. It has been reported that oleic acid and linoleic
acid can induce apoptotic death of breast cancer, lung cancer
prostate cancer, and lymphoma cells [35–38]. In our study,
we found that both oleic acid and linoleic acid has cytotoxic
eﬀect on AML cell lines HL-60 and U937 cells. Thus we
propose that the antileukemic eﬀect of BJO result mainly
from the existence of oleic acid and linoleic acid.
In summary, the present study ﬁrst demonstrated that
BJO possessed AntiLeukemia eﬀe c tb o t hi nv i t r oa n di nv i v o .
BJO induced AML cell apoptosis via both the mitochondrial
and death receptor apoptosis pathway by downregulating
c-FLIP(L/S), Mcl-1, Bcl-2, surviving, and XIAP. The data alsoEvidence-Based Complementary and Alternative Medicine 13
showed that oleic acid and linoleic acid were the active
components of BJO. These combined observations suggest
that BJO has a high potential for clinical application in the
treatment of AML.
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